Risk factors for potential drug-drug interactions of statins in patients with acute coronary syndrome
Abstract The aim of our study was to assess risk factors for potential drug-drug interactions (pDDIs) of statins across different phases of treatment of acute coronary syndrome (ACS) patients: from the point of first medical contact to the coronary angiography (first phase), after coronary angiograp...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Universidade de São Paulo
2022-06-01
|
| Series: | Brazilian Journal of Pharmaceutical Sciences |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502022000100602&tlng=en |
| _version_ | 1811342714906607616 |
|---|---|
| author | Ana V. Pejčić Slobodan M. Janković Goran Davidović |
| author_facet | Ana V. Pejčić Slobodan M. Janković Goran Davidović |
| author_sort | Ana V. Pejčić |
| collection | DOAJ |
| description | Abstract The aim of our study was to assess risk factors for potential drug-drug interactions (pDDIs) of statins across different phases of treatment of acute coronary syndrome (ACS) patients: from the point of first medical contact to the coronary angiography (first phase), after coronary angiography to the last day of hospitalization (second phase) and at discharge from hospital (third phase). This was a post hoc analysis of the data collected during the retrospective observational cohort study conducted at the Clinic for Cardiology of the Clinical Centre Kragujevac, Serbia. Patients prescribed statins were identified from the original study population: 156, 240 and 236 patients for the first, second and third phases, respectively. At least one statin pDDI was present in 113 (72.4%), 161 (67.1%) and 139 (58.9%) patients in the first, second and third phases, respectively. Heart failure, arrhythmias after ACS, CRP, triglycerides, length of hospitalization, number of prescribed drugs, antiarrhythmic drugs, and clopidogrel seem to increase the risk of statin pDDIs in at least one treatment phase. Physicians should be vigilant to the possibility of statin pDDIs in ACS patients who have factors that may increase their rate. |
| first_indexed | 2024-04-13T19:16:53Z |
| format | Article |
| id | doaj.art-7e891df2952045b0b1e72a6e7d21330f |
| institution | Directory Open Access Journal |
| issn | 2175-9790 |
| language | English |
| last_indexed | 2024-04-13T19:16:53Z |
| publishDate | 2022-06-01 |
| publisher | Universidade de São Paulo |
| record_format | Article |
| series | Brazilian Journal of Pharmaceutical Sciences |
| spelling | doaj.art-7e891df2952045b0b1e72a6e7d21330f2022-12-22T02:33:40ZengUniversidade de São PauloBrazilian Journal of Pharmaceutical Sciences2175-97902022-06-015810.1590/s2175-979020201000x22e19868Risk factors for potential drug-drug interactions of statins in patients with acute coronary syndromeAna V. Pejčićhttps://orcid.org/0000-0003-1741-0025Slobodan M. JankovićGoran DavidovićAbstract The aim of our study was to assess risk factors for potential drug-drug interactions (pDDIs) of statins across different phases of treatment of acute coronary syndrome (ACS) patients: from the point of first medical contact to the coronary angiography (first phase), after coronary angiography to the last day of hospitalization (second phase) and at discharge from hospital (third phase). This was a post hoc analysis of the data collected during the retrospective observational cohort study conducted at the Clinic for Cardiology of the Clinical Centre Kragujevac, Serbia. Patients prescribed statins were identified from the original study population: 156, 240 and 236 patients for the first, second and third phases, respectively. At least one statin pDDI was present in 113 (72.4%), 161 (67.1%) and 139 (58.9%) patients in the first, second and third phases, respectively. Heart failure, arrhythmias after ACS, CRP, triglycerides, length of hospitalization, number of prescribed drugs, antiarrhythmic drugs, and clopidogrel seem to increase the risk of statin pDDIs in at least one treatment phase. Physicians should be vigilant to the possibility of statin pDDIs in ACS patients who have factors that may increase their rate.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502022000100602&tlng=enStatinsAcute coronary syndromeDrug-drug interactionsRisk factors |
| spellingShingle | Ana V. Pejčić Slobodan M. Janković Goran Davidović Risk factors for potential drug-drug interactions of statins in patients with acute coronary syndrome Brazilian Journal of Pharmaceutical Sciences Statins Acute coronary syndrome Drug-drug interactions Risk factors |
| title | Risk factors for potential drug-drug interactions of statins in patients with acute coronary syndrome |
| title_full | Risk factors for potential drug-drug interactions of statins in patients with acute coronary syndrome |
| title_fullStr | Risk factors for potential drug-drug interactions of statins in patients with acute coronary syndrome |
| title_full_unstemmed | Risk factors for potential drug-drug interactions of statins in patients with acute coronary syndrome |
| title_short | Risk factors for potential drug-drug interactions of statins in patients with acute coronary syndrome |
| title_sort | risk factors for potential drug drug interactions of statins in patients with acute coronary syndrome |
| topic | Statins Acute coronary syndrome Drug-drug interactions Risk factors |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502022000100602&tlng=en |
| work_keys_str_mv | AT anavpejcic riskfactorsforpotentialdrugdruginteractionsofstatinsinpatientswithacutecoronarysyndrome AT slobodanmjankovic riskfactorsforpotentialdrugdruginteractionsofstatinsinpatientswithacutecoronarysyndrome AT gorandavidovic riskfactorsforpotentialdrugdruginteractionsofstatinsinpatientswithacutecoronarysyndrome |